Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $310.00 at Sanford C. Bernstein

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lowered by research analysts at Sanford C. Bernstein from $314.00 to $310.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s target price suggests a potential upside of 28.87% from the company’s previous close.

Several other research firms have also commented on ALNY. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Bank of America upped their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Trading Up 1.9 %

Shares of ALNY opened at $240.55 on Tuesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock’s 50-day moving average is $250.12 and its two-hundred day moving average is $259.54. The stock has a market cap of $31.03 billion, a PE ratio of -91.81 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 earnings per share. Equities analysts forecast that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This represents a 10.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,122 shares of company stock worth $2,540,455. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Huntington National Bank raised its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.